VidPrevtyn Beta COVID-19 booster approved in UK.- GSK
GSK announced the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) authorised Sanofi’s VidPrevtyn Beta COVID-19 booster SARS-CoV-2 spike protein (B.1.351 strain) vaccine for the prevention of COVID-19 disease in adults aged 18 and above in Great Britain, following the European Commission licence last month, which included Northern Ireland.
This SARS-CoV-2 spike protein (B.1.351 strain) vaccine is indicated as a booster for active immunisation to prevent COVID-19 in adults who have previously received a mRNA or adenoviral COVID-19 vaccine, and the use of this vaccine should be in accordance with official recommendations.
The approval is based on results from two separate immunogenicity trials, including one comparative trial with an approved mRNA booster as a comparator. In these registrational immunogenicity trials, carried out at times when the Omicron variant was predominantly circulating, the vaccine induced a neutralising antibody response against all tested variants of concern. This vaccine is based on the Beta variant spike antigen and includes GSK’s adjuvant. Across the registrational trials, the vaccine candidate was generally well-tolerated, with an acceptable safety profile.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.